Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. by Vickers, Madge R et al.
Vickers, MR; MacLennan, AH; Lawton, B; Ford, D; Martin, J; Mered-
ith, SK; De Stavola, BL; Rose, S; Dowell, A; Wilkes, HC; Dar-
byshire, JH; Meade, TW; WISDOM group (2007) Main morbidi-
ties recorded in the women’s international study of long duration oe-
strogen after menopause (WISDOM): a randomised controlled trial
of hormone replacement therapy in postmenopausal women. BMJ
(Clinical research ed), 335 (7613). p. 239. ISSN 0959-8138 DOI:
10.1136/bmj.39266.425069.AD
Downloaded from: http://researchonline.lshtm.ac.uk/9229/
DOI: 10.1136/bmj.39266.425069.AD
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
RESEARCH
Main morbidities recorded in the women’s international
study of long duration oestrogen after menopause
(WISDOM): a randomised controlled trial of hormone
replacement therapy in postmenopausal women
MadgeRVickers, former head,MRCgeneral practice research framework,1 Alastair HMacLennan, professor,
department of obstetrics and gynaecology,2 Beverley Lawton, director women’s health research centre,3
Deborah Ford, senior statistician,4 Jeannett Martin, former senior nurse manager,1 Sarah K Meredith, senior
clinical epidemiologist,4 Bianca L DeStavola, reader in biostatistics,5 Sally Rose, research fellow,3
Anthony Dowell, professor,3 Helen C Wilkes, senior statistician,4 Janet H Darbyshire, director,4
Tom W Meade, emeritus professor,5 for the WISDOM team
ABSTRACT
Objective To assess the long term risks and benefits of
hormone replacement therapy (combined hormone
therapy versus placebo, and oestrogen alone versus
combined hormone therapy).
DesignMulticentre, randomised, placebo controlled,
double blind trial.
Setting General practices in UK (384), Australia (91), and
New Zealand (24).
ParticipantsPostmenopausalwomenaged50-69 years at
randomisation. At early closure of the trial, 56583 had
been screened, 8980 entered run-in, and 5692 (26% of
target of 22300) started treatment.
InterventionsOestrogen only therapy (conjugated equine
oestrogens 0.625 mg orally daily) or combined hormone
therapy (conjugated equine oestrogens plus
medroxyprogesterone acetate 2.5/5.0 mg orally daily).
Ten years of treatment planned.
Main outcome measures Primary outcomes: major
cardiovascular disease, osteoporotic fractures, and
breast cancer. Secondary outcomes: other cancers, death
from all causes, venous thromboembolism,
cerebrovascular disease, dementia, and quality of life.
Results The trial was prematurely closed during
recruitment, after a median follow-up of 11.9 months
(interquartile range 7.1-19.6, total 6498 women years) in
those enrolled, after the publication of early results from
the women’s health initiative study. The mean age of
randomised women was 62.8 (SD 4.8) years. When
combined hormone therapy (n=2196) was comparedwith
placebo (n=2189), there was a significant increase in the
number of major cardiovascular events (7 v 0, P=0.016)
and venous thromboembolisms (22 v 3, hazard ratio
7.36 (95% CI 2.20 to 24.60)). There were no statistically
significant differences in numbers of breast or other
cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)),
cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)),
fractures (40 v58, 0.69 (0.46 to 1.03)), and overall deaths
(8 v 5, 1.60 (0.52 to 4.89)). Comparison of combined
hormone therapy (n=815) versus oestrogen therapy
(n=826) outcomes revealed no significant differences.
Conclusions Hormone replacement therapy increases
cardiovascular and thromboembolic risk when started
many years after the menopause. The results are
consistent with the findings of the women’s health
initiative study and secondary prevention studies.
Research is needed to assess the long term risks and
benefits of starting hormone replacement therapy near
the menopause, when the effect may be different.
Trial registration Current Controlled Trials ISRCTN
63718836
INTRODUCTION
Although the use of hormone replacement therapy for
control ofmoderate to severemenopausal symptoms is
well established, its long term use for disease preven-
tion in postmenopausal women is in dispute.1-3 Ten
randomised controlled trials have investigated the
risks and benefits of hormone replacement therapy in
postmenopausal women.4-13 Three trials in the United
States,4 7 12 two in the United Kingdom,89 and one in
Estonia13 showed that such therapy does not protect
against development of cardiovascular disease and
may increase the risk.
In the largest trial, and the only one designed to
assess the prevention of cardiovascular disease, the
US women’s health initiative study, women aged
50-79 years taking combined oestrogen and progesto-
gen had a significantly increased risk of stroke, pul-
monary embolism, and breast cancer and a decreased
risk of hip fracture and colorectal cancer compared
with women taking placebo.7 This study found that
combined oestrogen and progestogen therapy might
increase coronary events in older women (aged 70-
79) in their first year of treatment.14 Overall, the risks
seen in the women’s health initiative study were likely
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to outweigh the benefits, and the combined oestrogen
and progestogen arm of the trial was closed prema-
turely after a mean of 5.2 years of follow-up. Later,
the oestrogen only arm of the trial in women who had
had a hysterectomy was also closed prematurely, after
an average of 6.8 years of follow-up, as it showed an
increased risk of stroke but no overall difference in
cardiovascular disease or breast cancer.12
In 1989 the UK Medical Research Council agreed
that a randomised controlled trial to assess the long
term benefits and risks of hormone replacement ther-
apywas apriority. Successful feasibility trialswere con-
ducted, and, after extensive review, funding from
multiple sources was secured for the women’s inter-
national study of long duration oestrogen after meno-
pause (WISDOM), which began recruitment in
1999.15 16 The women’s health initiative study had
begun in 1997, enrolling women aged 50-79 for an
expected average of 8.5 years of follow-up. WISDOM
was originally designed to investigate a younger age
group (45-60 years old) to ensure the data were rele-
vant to the normal use of hormone replacement ther-
apy, but this was latermodified to 50-64 years and then
extended to 69 years to increase the likelihood of rele-
vant events during the trial planned for 10 years treat-
ment with a further 10 years’ follow-up (later modified
to five years).16 The aim was to recruit 22300 postme-
nopausal women and to assess the balance of long term
risks and benefits of hormone replacement therapy
with particular emphasis on cardiovascular disease
and dementia. The design allowed for two main com-
parisons: combined oestrogen and progestogen ther-
apy versus placebo and, in women who had had a
hysterectomy, oestrogen alone versus combined oes-
trogen and progestogen therapy.
Recruitment began in theUK in 1999 and inAustra-
lia and New Zealand in 2000. Recruitment was still
under way when the MRC stopped the trial after the
first results of the combined oestrogen and progesto-
gen arm of the women’s health initiative study were
published in 2002. This paper presents the main clin-
ical outcomes forWISDOMafter 6498 person years of
follow-up for a median of 11.9 months.
METHODS
Setting
Recruitment took place in general practice. In the UK
participants were recruited through 384 general prac-
tices from theMRCGeneral Practice Research Frame-
work. In addition, 91 general practices inAustralia and
24 in New Zealand participated.
Participants
Full details of recruitment procedures and other meth-
ods are published elsewhere.17 In each country we
identified women aged 50-69 years from practice reg-
isters. Where possible, patients’ notes were searched
by a research nurse to exclude ineligible women. Post-
menopausal women (no menstrual period in the past
12 months or had undergone hysterectomy) were eli-
gible for the trial.
The exclusion criteria are described in full
elsewhere.17 Main exclusion criteria were a history of
breast cancer; any other cancer in the past 10 years
except basal and squamous cell skin cancer; endo-
metriosis or endometrial hyperplasia; venous throm-
boembolism; gall bladder disease in women who had
not had a cholecystectomy; andmyocardial infarction,
unstable angina, cerebrovascular accident, subarach-
noid haemorrhage, transient ischaemic attack, or use
of hormone replacement therapy within the past six
months.Women takinghormone replacement therapy
at screening who were prepared to enter the placebo
controlled strata of the study agreed to stop the therapy
for three months before the run-in phase. During run-
in they took placebo so that at randomisation they had
not taken hormone replacement therapy for six
Note searches or eligibility checks (n=284 175)
Patients eligible (n=226 282)
Practices withdrew from the trial (n=796)
No reply/temporary patient/returned undelivered (n=14 891)
Ineligible (n=22 263)
Unwilling (n=56 101)
Willing but had not yet attended screening interview by trial closure (n=4570)
Ineligible (n=57 893)
Not yet invited to screening at time of trial closure (n=71 078)
Invited to screening (n=155 204)
Attended screening (n=56 583)
Entered run-in phase (n=8980)
Ineligible (n=6789)
Unwilling (n=35 591)
Eligible and willing but had not yet attended run-in visit at time of trial closure (n=5223)
Eligible and gave consent  (n=5692)
Stratum 1 (n=3721) Stratum 2 (n=966) Stratum 3 (n=1005)
Ineligible (n=2176)
Unwilling (n=1022)
Willing but had not been randomised by trial closure (n=90)
Randomised to treatment Randomised to treatment
Combined
therapy
(n=1862)
Placebo
(n=1859)
Randomised to treatment
Placebo
(n=2189)
Combined therapy
(n=2196)
Combined therapy
(n=815)
Oestrogen therapy
(n=826)
Oestrogen
therapy
(n=485)
Combined
therapy
(n=481)
Oestrogen
therapy
(n=341)
Combined
therapy
(n=334)
Placebo
(n=330)
Flow of patients through the women’s international study of long duration oestrogen after
menopause (WISDOM). (Trial closure was on 22 October 2002. Combined therapy=conjugated
equine oestrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg orally daily. Oestrogen
therapy=conjugated equine oestrogen 0.625 mg orally daily)
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months.Womenwhowere, in the opinion of their gen-
eral practitioner, unlikely to be able to give informed
consent or successfully complete trial procedures were
also excluded.
Eligible women and those whose notes were not
available were contacted by post and invited to attend
a screening session with a research nurse at their prac-
tice. In Australia patients were invited first to group
sessions to learn more about hormone replacement
therapy and the trial before volunteering for screening,
whereas in the UK and New Zealand the research
nurse discussed these details at the interview. The strat-
egywas to recruit the oldest women first.Women com-
pleted a screening questionnaire, were provided with
written information, and, if, after consideration for two
weeks, they were willing to participate, provided writ-
ten consent, and entered a 12 week run-in period (fig-
ure). All women took medication during run-in:
women who were willing to enter a placebo controlled
randomisation took placebo and women who had
undergone a total hysterectomy and were willing
only to enter a comparison of two active treatments
took oestrogen only. Four weeks before the end of
run-in, eligible womenwho had achieved 80% compli-
ance were invited to enter the trial and were rando-
mised to treatment (figure).
Method of random allocation
Treatment was randomly allocated centrally with a
computer based, stratified block randomisation pro-
gram. Stratification was based on hysterectomy status
and intended use of hormone replacement therapy.
Women with a uterus or subtotal hysterectomy (stra-
tum 1 of the study) were randomised to combined oes-
trogen plus progestogen or to placebo using a block
size of 16. Women with no uterus and unwilling to
take placebo were randomised to either oestrogen
only or combined oestrogen and progestogen therapy
(stratum 2) using a block size of 16, and those willing to
enter a placebo controlled comparison were rando-
mised to oestrogen, combined oestrogen plus proges-
togen, or placebo using a block size of 24 (stratum 3).
Within each stratum there was equal probability of
allocation to any of the treatment arms.
As soon as the woman was randomised the appro-
priate treatment packwas issued from the central store,
labelled for the participant and dispatched to the prac-
tice. Drugs were packed in foils containing tablets for
28 days. Within each stratum the drug packaging for
each arm of the trial was identical. Randomised treat-
ment was started if, at the end of run-in, the woman
remained eligible and willing to enter the trial.
Interventions
The oestrogen therapy was conjugated equine oestro-
gens (Premarin, Wyeth Ayerst US), 0.625 mg orally
daily. The combined therapy was conjugated equine
oestrogens as above plus medroxyprogesterone acet-
ate 2.5 mg orally daily (Prempro, Wyeth Ayerst US).
Women with a uterus and within three years of their
last period, those aged 50-53, and older women with
unacceptable breakthrough bleeding took 5.0 mg
medroxyprogesterone acetate (Premique, Wyeth
Ayerst US). Women with a uterus who experienced
unacceptable spotting or bleeding with the combined
therapy containing 5.0mgmedroxyprogesterone acet-
ate were offered open label Premique cycle (Premarin
0.625 mg orally daily plus medroxyprogesterone acet-
ate 10 mg orally for the last 14 days of a 28 day cycle).
The plannedmedian treatment duration of the trial
was 10 years (range 9-12), with treatment being co-
terminous in all participants. As far as possible, the
trial was conducted in a double-blind manner,
though full blindness could not be maintained when
vaginal bleeding triggered a code break and investi-
gation for possible pathology.
Data collection
Womenwere to be seen at 4, 14, 27, 40, and 52 weeks
after start of treatment and then at six month inter-
vals. A final visit took place as soon as possible after
the closure of the trial. At the start of treatment and at
each follow-up visit, information was collected on all
outcomes, adverse events, and other medical history
to check that patients remained eligible. The research
nurse entered data directly on to a customisedAccess
database that incorporated extensive checks for plau-
sibility, consistency, and completeness. Data were
sent by modem link (UK) or via a standard File
Transfer Program server site (Australia and New
Zealand) to the coordinating centre within one
week of collection. A member of the study team,
who was blinded to treatment allocation, obtained
any data needed to confirm a clinical event from the
general practice, hospital, or coroner.
Main clinical outcome measures
Primary outcomes were major cardiovascular dis-
ease (defined as one or more of unstable angina
requiring hospitalisation, fatal or non-fatal myo-
cardial infarction, or sudden coronary death), osteo-
porotic fractures (all fractures other than of the skull,
face, cervical spine, fingers, or toes), and breast can-
cer. Secondary outcomes were breast cancer mortal-
ity, other cancers, death from all causes, venous
thromboembolism (deep vein thrombosis, pulmon-
ary embolism, or retinal vein occlusion), cerebro-
vascular disease, and dementia. Quality of life and
psychological wellbeing were measured and are
reported separately. All outcomes were reviewed
blind to treatment allocation. All cardiovascular
and cancer outcomes and 10% of fractures were
reviewed by independent assessors.
Participants were asked about symptoms and
adverse events at each visit. Each adverse event was
assessed for seriousness according to defined criteria
in the protocol. Reporting of certain potential
complications of hormone replacement therapy—
such as gallbladder disease, sudden loss of vision, or
diplopia—required the nurse to interrupt treatment
temporarily.
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Sample size
WISDOM was designed to detect a 25% reduction in
the number of cases of coronary heart disease (exclud-
ing unstable angina) and stroke over 10 years compar-
ing combined oestrogen and progestogen therapywith
placebo in women aged 50-64 years at randomisation.
A total sample size of 18000, assuming 13000were tak-
ing combined therapy or placebo in strata 1 and 3, pro-
vided 80% power at the 5% significance level.
The primary outcome was subsequently changed to
exclude stroke and to include unstable angina, and the
age range at randomisation was extended to 69 years.
Other assumptions were modified. In particular,
cardiovascular event rates were reduced as these were
falling faster than expected in the populations of the
countries involved and estimates of withdrawal rates
were revised. The expected maximum recruitment of
22300 (16000 for combined therapy versus placebo)
provided 80% power at the 5% significance level to
detect a 29% reduction from an expected probability
of a primary outcome event in the placebo group dur-
ing the trial period of 39 per 1000 women randomised.
This sample size also had the power to detect a 20%
reduction, from an expected probability of 95 per
Table 1 | Characteristics of participants inWISDOMat randomisation by treatment group. (Values are numbers (percentages)
unless stated otherwise
Participant characteristics
Combined therapy v placebo*
Combined therapy v oestrogen
therapy†
Combined therapy
(n=2196) Placebo (n=2189)
Combined
therapy (n=815)
Oestrogen therapy
(n=826)
Sociodemographic variables
Mean (SD) age at randomisation (years) 63.3 (4.7) 63.3 (4.6) 61.7 (5.1) 61.9 (5.1)
Age at randomisation:
50-54 years 145 (7) 131 (6) 93 (11) 96 (12)
55-59 years 395 (18) 419 (19) 219 (27) 205 (25)
60-64 years 716 (33) 732 (33) 262 (32) 268 (32)
≥65 years 938 (43) 906 (41) 241 (30) 257 (31)
Mean (SD) years since menopause (last menstruation) 14.8 (7.2) 14.7 (7.1) 18.2 (7.4) 17.9 (7.5)
Non-white ethnic status 23/2174 (1) 30/2163 (1) 16/802 (2) 16/815 (2)
Left full time education before 16 years old 1607 (73) 1564 (71) 611 (75) 615 (75)
Using HRT at screening: 167 (8) 184 (8) 430 (53) 429 (52)
Median (interquartile range) duration of use (years) 8 (5.3-11) 10 (4.6-10.2) 10 (6.6-12) 10 (6.5-12.7)
Ever used HRT at screening: 1041 (47) 1005 (46) 646 (79) 648 (79)
Median (interquartile range) duration of use (years) 3.8 (0.8-8) 4 (0.9-8) 8 (4-11.4) 8 (4.1-1.3)
Cardiovascular risk factors
Mean (SD) body mass index 27.9 (4.9) 28.0 (5.2) 28.0 (4.7) 27.9 (5.0)
Body mass index:
<25 629 (29) 659 (30) 231 (28) 250 (30)
25-29 934 (43) 848 (39) 356 (44) 330 (40)
≥30 623 (28) 675 (31) 226 (28) 243 (30)
Mean (SD) systolic blood pressure (mm Hg) 136 (21) 137 (22) 137 (21) 135 (20)
Mean (SD) diastolic blood pressure (mm Hg) 73 (10) 73 (10) 74 (10) 73 (10)
Current smoker 256 (12) 309 (14) 89 (11) 118 (14)
Former smoker‡: 664 (30) 633 (29) 256 (31) 238 (29)
Median (interquartile range) time since stopping (years) 18 (9-29) 18 (9-28) 18 (8-26) 20 (9-30)
Previous angina 127 (6) 104 (5) 51 (6) 41 (5)
Previous myocardial infarction 40 (2) 26 (1) 17 (2) 10 (1)
Previous stroke 30 (1) 38 (2) 16 (2) 12 (1)
History of diabetes 70 (3) 93 (4) 28 (3) 30 (4)
Breast cancer risk factors
1st degree female relative with breast cancer 149/1954 (8) 183/1956 (9) 67/723 (9) 59/740 (8)
Current non-drinker 354 (16) 332 (15) 120 (15) 132 (16)
Osteoporotic fracture risk factors
Previous fracture past age of 50 390 (18) 397 (18) 110 (13) 118 (14)
Maternal osteoporosis 179/2161 (8) 166/2138 (8) 77/793 (10) 87/812 (11)
Overall quality of life
Mean (SD) visual anologue scale (of 0-100) 78.5 (14) 77.7 (14) 77.6 (15) 77.0 (15)
All variables are affected by missing values. HRT = hormone replacement therapy.
*Combined therapy = conjugated equine oestrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg orally daily.
†Oestrogen therapy = conjugated equine oestrogen 0.625 mg orally daily.
‡Number of past smokers who had recorded a time since stopping smoking.
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1000 women, in all osteoporotic fractures and a 40%
increase, from an expected probability of 36 per 1000
women, in breast cancer.
The predicted withdrawal from randomised treat-
ment was 36% (10% in the first year of treatment, 7% in
year 2, 4% in year 3, 3% in year 4, and 2% in years 5-10),
and the associated attenuation of observed differences
between randomised groups was taken into account in
the power calculations. Based on feasibility studies and
current use of hormone replacement therapy, it was
assumed that 20% of women would be 65-69 years
with 80% distributed equally across the three five-year
age bands 50-54, 55-59, and 60-64 years. Full details of
the assumptions made for the event rates in the placebo
group are reported elsewhere.17
Statistical methods
Follow-up time for each participant was calculated for
each outcome separately from date of randomisation
until the date of outcome, of death, of loss to follow-up,
or of trial closure, whichever occurred first. The out-
comes of interest were cardiovascular disease, cerebro-
vascular disease, venous thromboembolism, fractures,
cancer, and death. We adopted the intention-to-treat
principle when assessing treatment effects, with
P<0.05 used to define statistical significance. We clas-
sified participants according to randomisation group
and compared combined oestrogen plus progestogen
therapy with placebo (pooling data from women from
strata 1 and 3), and combined therapy with oestrogen
only therapy (combining strata 2 and 3). Women from
stratum 3 who were randomised to combined therapy
were thereby included in both comparisons.
To account for the prospective nature of the data, we
calculated event rates (per 10000 women-years) as the
number of events divided by the relevant accumulated
person-time—that is, assuming a Poisson regression
(constant hazards) model. We calculated hazard ratios
under the more flexible Cox proportional hazards
model, after graphically checking its assumptions.18
The results are reported as, respectively, rates and
hazard ratios for the effect of combined therapy versus
either placebo or oestrogen therapy (with 95%
confidence intervals), with associated likelihood ratio
tests for significance.18 No adjustment was made for
multiple a priori testing.
Table 2 | Characteristics of all women screened forWISDOMand thosewhowere randomised. (Values are numbers (percentages)
unless stated otherwise
Characteristics Randomised (n=5692) Screened (n=56468)
Sociodemographic variables
Mean (SD) age at randomisation (years) 62.9 (4.8) 61.4 (4.9)
Age at randomisation:
50-54 years 437 (8) 8390 (15)
55-59 years 1177 (21) 14768 (26)
60-64 years 1876 (33) 19087 (34)
≥65 years 2199 (39) 14223 (25)
Non-white ethnic status 80/5623 (1) 1174/54008 (2)
Using HRT at screening: 1175 (21) 17578 (31)
Median (interquartile range) duration of use (years) 9 (6-12) 9 (5.2-12)
Ever used HRT at screening: 3144 (55) 32309 (57)
Median (interquartile range) duration of use (years) 5.3 (1.5-10) 6.2 (2-10)
Cardiovascular risk factors
Mean (SD) body mass index 28.0 (5.0) 27.4 (5.0)
Mean (SD) systolic blood pressure (mm Hg) 136.2 (21) 142 (23)
Mean (SD) diastolic blood pressure (mm Hg) 73.1 (10) 76 (11)
Current smoker 738 (13) 6794 (12)
Former smoker 1782 (31) 15095 (27)
Previous unstable angina 297 (5) 2919 (5)
Previous myocardial infarction 84 (1) 887 (2)
Previous stroke 90 (2) 1261 (2)
History of diabetes 210 (4) 1932 (3)
Breast cancer risk factors
1st degree female relative with breast cancer 434/5080 (9) 4755/50372 (9)
Current non-drinker 882 (16) 10321 (18)
Osteoporotic fracture risk factors
Previous fracture past age of 50 959 (17) 7405 (13)
Overall quality of life
Mean (SD) visual anologue scale (of 0-100) 77.9 (14) 76.0 (16)
All variables are affected by missing values.
*Data for 115 New Zealand women screened were lost during electronic transmission.
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RESULTS
Recruitment
A total of 284175 women aged 50-69 years were regis-
tered at the participating practices (224075 from the
UK, 36210 fromAustralia, and 23890 fromNew Zeal-
and), of whom 226282 were potentially eligible for the
trial (figure). When the trial closed on 22 October
2002, 155204 women (68% of those potentially eligi-
ble) hadbeen invited to screening, 56583had attended,
and 4570 had agreed to attend but had not yet been
interviewed. Of those screened and eligible, 14203
(29%) agreed to enter the run-in phase, of whom 8980
had entered at the time of closure. At the end of run-in,
5692 participants remained eligible, gave consent,
were randomised, and started trial treatment (26% of
the target of 22300; 5250 from the UK, 319 from Aus-
tralia, and 123 from New Zealand).
Baseline data
The participants’ mean age was 62.8 years (SD 4.8),
reflecting the strategy of recruiting older women first.
Women who had undergone a hysterectomy were, on
average, slightly younger andweremore likely to have
ever used hormone replacement therapy and to have
used it for a longer time than those women with a
uterus.Womenwhowere not willing to accept placebo
randomisation (stratum 2) were more likely to have
used hormone replacement therapy and to be using it
at screening (82%). Other characteristics were similar
for the three strata. The characteristics of the treatment
groups for both the comparison groups of combined
therapy versus placebo and oestrogen therapy versus
combined therapy were also similar (table 1).
In the main treatment comparison (combined ther-
apy versus placebo) 8% in each group were using hor-
mone replacement therapy at screening and 46-47% of
those screened were past users of hormone replace-
ment therapy for a median of 3.8-4 years. Data from
the screening interviews indicate that, with regard to
major risk factors for the primary outcomes, WIS-
DOM participants were similar to women screened
in the participating practices (table 2), although
screened women had greater current use of hormone
replacement therapy (31%) than randomised women
(21%). The mean number of years since menopause
(last menstrual period) in all women with a uterus was
13.8 (SD 6.7). The mean number of years since last
menstrual period or hysterectomy with or without
oophorectomy in all women without a uterus (strata 2
and 3) was 18.5 (SD 7.5). In the main comparison of
combined therapy versus placebo, which included
women with and without a uterus from strata 1 and 3,
the mean years from last menstrual period were 14.8
and 14.7 respectively.
Follow up
With the early closure of the trial themedian follow-up
time was 11.9 months (interquartile range 7.3-19.6),
with a total follow-up time of 6498 women years. In
women randomised to combined therapy or placebo,
median follow-up was 12.8 (7.5-20.4) months, with a
total of 5214 person-years; for women randomised to
combined therapy or oestrogen therapy the figures
were 10.3 (6.4-16.8) months and 1688 years, respec-
tively. Five participants were lost to follow-up.
By 15 July 2002, when the results from the women’s
health initiative study were disseminated, 725 women
(12.7%) had withdrawn from randomised treatment;
most were in stratum 1 (369 taking combined therapy;
162 taking placebo) or stratum 3 (46 taking combined
therapy; 50 taking oestrogen therapy, and 38 taking
placebo). Table 3 gives the reasons for withdrawal.
An additional 368 women were taking a temporary
interruption of trial treatment at the time the women’s
health initiative reported; of these, only 23 restarted
randomised treatment before trial closure.
Table 3 | Reasons for withdrawal fromWISDOMbefore 15 July 2002. (Values are numbers (percentages))
Reasons‡
Combined therapy v placebo* Combined therapy v oestrogen therapy†
Combined therapy
(n=430) Placebo (n=203)
Combined therapy
(n=88)
Oestrogen therapy
(n=78)
Vaginal bleeding 122 (28) 2 (1) 0 0
Other potentially HRT related symptoms 94 (22) 18 (9) 23 (27) 14 (18)
Concerns about risks of HRT 33 (8) 17 (8) 8 (9) 10 (13)
Social (such as moved) 22 (5) 24 (12) 6 (7) 10 (13)
No longer wished to be in a trial 16 (4) 33 (16) 5 (6) 1 (1)
Protocol excluded outcome 22 (5) 5 (2) 6 (7) 2 (3)
Other protocol exclusion 3 (1) 3 (1) 0 1 (1)
Cardiac outcome 5 (1) 1 (0.5) 1 (1) 1 (1)
Cerebrovascular outcome 2 (0.5) 6 (3) 1 (1) 1 (1)
Menopausal symptoms 2 (0.5) 10 (5) 1 (1) 1 (1)
Non-trial HRT prescription 1 (0) 3 (1) 3 (3) 3 (4)
Other diagnoses or symptoms 103 (24) 66 (33) 28 (33) 30 (38)
Unknown 5 (1) 15 (7) 4 (5) 2 (3)
HRT = hormone replacement therapy.
*Combined therapy = conjugated equine oestrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg orally daily.
†Oestrogen therapy = conjugated equine oestrogen 0.625 mg orally daily.
‡More than one reason may be given.
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Table 4 | Primary and secondary clinical outcomes inWISDOMby timeof follow-up and randomised treatment*
Outcomes All (n=5692)
Combined therapy v placebo Combined therapy v oestrogen therapy
Combined therapy
(n=2196) Placebo (n=2189)
Combined therapy
(n=815)
Oestrogen therapy
(n=826)
Cardiovascular disease
Unstable angina 6 3 0 3 1
Non-fatal myocardial infarct 6 4 0 1 2
Fatal myocardial infarct 0 0 0 0 0
Sudden coronary death 1 0 0 0 1
Any of the above 11 7 0 4 2
Rate (95% CI)† 17.0 (9.4 to 30.6) 26.9 (12.8 to 56.4) 0 47.8 (18.0 to 127.5) 23.6 (5.9 to 94.4)
Hazard ratio (95% CI); P value NA; 0.016 2.03 (0.37 to 11.09); 0.40
Cerebrovascular disease
Non-fatal 36 13 19 4 4
Fatal 1 1 0 0 0
Fatal or non-fatal 37 14 19 4 4
Rate (95% CI)† 57.2 (41.4 to 78.9) 53.8 (31.9 to 90.9) 73.4 (46.8 to 115.0) 47.9 (18.0 to 127.6) 47.1 (17.7 to 125.6)
Hazard ratio (95% CI); P value 0.73 (0.37 to 1.46); 0.38 1.01 (0.25 to 4.04); 0.99
Venous thromboembolism
Deep vein thrombosis 18 13 1 5 3
Pulmonary embolism 14 10 2 2 1
Fatal thromboembolism 3 2 0 0 1
Any of the above 30 22 3 7 3
Rate (95% CI)† 46.4 (32.4 to 66.3) 85.1 (56.0 to 129.2) 11.5 (3.7 to 35.7) 84.3 (40.2 to 176.9) 35.3 (11.4 to 109.5)
Hazard ratio (95% CI); P value 7.36 (2.20 to 24.60); <0.001 2.39 (0.62 to 9.24); 0.19
Osteoporotic fractures
Hip 5 2 3 1 0
Other 108 38 55 11 8
Any 113 40 58 12 8
Rate (95% CI)† 176.1 (146.5 to
211.8)
155.3 (114.0 to
211.8)
226.2 (174.9 to
292.6)
144.5 (82.1 to254.4) 94.4 (47.2 to 188.8)
Hazard ratio (95% CI); P value 0.69 (0.46 to 1.03); 0.07 1.52 (0.62 to 3.72); 0.35
Cancer
Breast 16 5 7 3 2
Colorectal 6 2 2 1 2
Other 37 15 16 4 3
Any 59 22 25 8 7
Rate (95% CI)† 91.3 (70.7 to 117.8) 84.8 (55.8 to 128.7) 96.5 (65.2 to 142.8) 96.0 (48.0 to 192.0) 82.8 (39.5 to 173.6)
Hazard ratio (95% CI); P value 0.88 (0.49 to 1.56); 0.65 1.16 (0.42 to 3.20); 0.78
Death
Breast cancer 0 0 0 0 0
Colorectal cancer 1 1 0 1 0
Other cancer 5 2 3 0 0
Cardiovascular 1 0 0 0 1
Cerebrovascular 1 1 0 0 0
Venous thromboembolism 3 2 0 0 1
Other causes 4 2 2 0 0
All death 15 8 5 1 2
Rate (95% CI)† 23.1 (13.9 to 38.3) 30.7 (15.3 to 61.3) 19.2 (8.0 to 46.1) 11.9 (1.7 to 84.7) 23.5 (5.9 to 94.0)
Hazard ratio (95% CI); P value 1.60 (0.52 to 4.89); 0.40 0.51 (0.05 to 5.58); 0.57
Any event 242 99 104 35 23
Rate (95% CI)† 382.7 (337.4 to
434.0)
390.9 (321.0 to
476.1)
410.9 (339.0 to
497.9)
429.9 (308.6 to
598.7)
274.6(182.5to413.2)
Hazard ratio (95% CI); P value 0.95 (0.72 to 1.25); 0.72 1.56 (0.92 to 2.64); 0.09
*Some events appear in both comparisons
†Rate is per 10000 women-years.
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During follow-up of women randomised to com-
bined therapy or placebo, trial treatment was supplied
for 73% of time at risk in women allocated to active
treatment (27% of time at risk was after withdrawal or
during a temporary interruption of treatment) and for
86%of time at risk inwomen allocated to placebo.Cor-
responding proportions in women randomised
between combined therapy and oestrogen therapy
were 83% and 84% respectively.
The treatment code was unblinded in only two of
the 1971 women who had undergone hysterectomy,
but in womenwith a uterus the proportion unblinded
was high, mostly as a result of vaginal bleeding in
those randomised to combined therapy, where 712/
1862 (38%) were unblinded, compared with 66/1859
(4%) of those randomised to placebo (hazard ratio
13.4 (95% confidence interval 10.4 to 17.3),
P<0.001).
Clinical outcomes
The total number of events for all trial outcomes was
low because the trial was stopped early. There are no
data on dementia because the first follow-up assess-
ment was planned for two years after randomisation.
Combined oestrogen and progestogen therapy versus
placebo
Compared with those taking placebo, women taking
combined therapy had significantly increased rates of
cardiovascular events (26.9 v 0 per 10000 women-
years, P=0.016) and venous thromboembolism (85.1
v 11.5 per 10000 women-years, hazard ratio 7.36
(2.20 to 24.60), P<0.001) and a non-significant reduc-
tion in the rate of osteoporotic fractures (155.3 v 226.2
per 10000 women-years, hazard ratio 0.69 (0.46 to
1.03), P=0.07) (table 4). Rates for cerebrovascular dis-
ease, breast cancer, and other cancers were not signifi-
cantly different in the two groups.
Cardiovascular events
The 11 cardiovascular events recorded were all in
women randomised to hormone replacement therapy
(nine to combined therapy and two to oestrogen ther-
apy). All but two of these womenwere over 64 years of
age at trial entry and had one or more cardiovascular
risk factors (three had a history of myocardial infarc-
tion or angina, two had diabetes, four smoked, and
eight had a body mass index ≥25).
Cerebrovascular events
There was no significant difference in cerebrovascular
events with a rate of 73.4 (95% confidence interval 46.8
to 115.0) per 10000 women-years in the placebo group
and 53.8 (31.9 to 90.9) in the combined therapy group
(hazard ratio 0.73 (0.37 to1.46), P=0.38).When transient
ischaemic attackswereexcluded thedifferencesbetween
the treatment groups were even smaller, with a hazard
ratio of 0.91 (0.39 to 2.14) for combined therapy versus
placebo and oestrogen therapy and 1.01 (0.21 to 5.02)
for combined therapy versus oestrogen therapy.
Oestrogen and progestogen versus oestrogen alone
The numbers of participants and the number of events
in this comparison are much smaller than for the com-
parison of combined oestrogen plus progestogen ver-
sus placebo (table 4). There is a suggestion in the
combined therapy group of an increase in cardio-
vascular events (47.8 v 23.6 per 10000 women-years,
hazard ratio 2.03 (0.37 to 11.09), P=0.40) and in venous
thromboembolism (84.3 v 35.3 per 10000 women-
years, hazard ratio 2.39 (0.62 to 9.24), P=0.19).
Adverse events
There were 15 deaths during the trial, with a non-signifi-
cant increase in the rate in the combined therapy group
compared with placebo (30.7 v 19.2 per 10000 women-
years, hazard ratio 1.60 (0.52 to 4.89)). Serious adverse
events by diagnostic category and treatment group are
Table 5 | Numbers of serious adverse events among participants inWISDOMby treatment group
Serious adverse events
Combined therapy v placebo* Combined therapy v oestrogen therapy†
Combined therapy
(n=2196) Placebo (n=2189)
Combined therapy
(n=815)
Oestrogen therapy
(n=826)
Visual disturbance 19 33 12 5
Gallbladder disease 13 13 10 10
Genitourinary 9 7 3 1
Cardiac and vascular 9 7 1 3
Musculoskeletal and rheumatic 7 18 7 3
Gastrointestinal 5 10 4 3
Other ophthalmic and neuropsychiatric 5 3 1 0
Other hepatobilliary disorders 2 3 1 2
Respiratory and ear, nose, and throat 2 6 0 6
Haematological and endocrine 2 4 1 0
Dermatological 1 3 0 1
Miscellaneous symptoms and other 0 2 1 4
All adverse events 74 109 41 38
*Combined therapy = conjugated equine oestrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg orally daily.
†Oestrogen therapy = conjugated equine oestrogen 0.625 mg orally daily.
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listed in table 5. There was no excess of serious adverse
events in either of the randomised comparisons.
DISCUSSION
Data from WISDOM suggest that women starting or
restarting combined oestrogen and progestogen therapy
an average of 14 years after menopause are at increased
risk of cardiovascular disease and venous thromboem-
bolism, at least in the early years of treatment.We found
a trend towards a decreased risk of osteoporotic fracture
and no difference in the risk of stroke or cancers. The
small numbers of events and the brief follow-up periods
inevitably mean that some of the results cannot be con-
fidently interpreted. However, we can comment on the
results forearly cardiovascular and thromboembolicdis-
ease. In a direct comparison with combined oestrogen
and progestogen therapy, oestrogen only therapy may
have similar, but smaller, short term effects. These
results are consistent with the findings of the combined
oestrogen and progestogen therapy arm of the women’s
health initiative study and with secondary prevention
trials, and support the conclusion that combined oestro-
gen and progestogen therapy should not be given for
cardiovascular disease prevention in older postmeno-
pausal women.47-9
Value of study
Despite the fact that WISDOM did not run to com-
pletion, this trial makes an important contribution to
the body of knowledge about hormone replacement
therapy started in older postmenopausal women of a
mean age of 63 years. TheWISDOMpopulation was
recruited from women on general practice registers
in countries where health care is free or with low fees.
The randomised women had a similar health profile,
with regard to the factors of interest in the trial, as
those in the same age range who were first screened.
With the exception of a history of breast cancer, a
family history of venous thromboembolism, and
other exclusion factors that would have made them
less likely to take hormone replacement therapy, the
WISDOM participants were similar to the registered
population and to the UK population of the same age
range.19 A strength of the study is that participants are
likely to be representative of the general population
of women of this age and the results applicable to this
older age group. Comparing the population in the
women’s health initiative study, many of the
women in WISDOM were similarly overweight or
obese and had many similar cardiovascular risk
factors.7 12 The mean age at entry was also similar.
However, previous use of hormone replacement
therapy was higher in WISDOM than in the
women’s health initiative study (45% compared
with 26% in women with a uterus).
Comparison of results
For combined oestrogen and progestogen therapy, the
WISDOM results are similar to the findings in the
early years of the women’s health initiative trial.
Venous thromboembolism—The event rate in women
taking combined oestrogen and progestogen therapy
in WISDOM was higher than that reported in the
early years of the women’s health initiative trial,
despite the exclusion in WISDOM of those with pre-
vious events. The reason for this is not clear but, in view
of the small numberof events,maybe a chance finding.
The increased rate of venous thromboembolism with
combined therapy was greatest in the first year of the
women’s health initiative trial.7 It is possible that those
with genetic predisposition to thrombosis have early
vulnerability to hormone replacement therapy.20
Cardiovascular disease—Although the number of
cardiovascular events observedwas small, all occurred
in the hormone replacement therapy groups, at a rate
of 27 per 10000women-years in the combined therapy
arm of WISDOM. This rate was smaller than the rate
of 51 per 10000 women-years in the first year of the
combined therapy armof thewomen’s health initiative
study. The early increased risk of cardiovascular
events in both trials is compatible with the hypothesis
that administration of hormone replacement therapy,
particularly combined oestrogen and progestogen
therapy, to women many years after menopause, who
are likely to have established atherosclerosis, may
cause disruption of the plaque surface,with subsequent
platelet adhesion, clotting, and further arterial
narrowing.21Most of the events inWISDOMoccurred
in women over the age of 64, many of whom had
cardiovascular risk factors.
Fractures—The non-significant trend toward a
reduced risk of fractures after an average follow-up
period of only one year is in keeping with the signifi-
cant reduction of fractures seen in the women’s health
initiative study.7 12 Neither WISDOM nor the
women’s health initiative study required an increased
risk of fracture as an inclusion criterion, and so the
results suggest a potent preventive effect in an
unscreened population. As in the women’s health
initiative study, we found no apparent difference
between combined therapy and oestrogen therapy in
their effect on fracture prevention.
Cancer—We found no effect on cancer rates, includ-
ing breast cancer, but thismust be interpretedwith cau-
tion as the maximum follow-up was three years
(median one year). A decrease in the annual risk of
breast cancer of 7 per 10000 cases compared with pla-
cebo after nearly seven years of oestrogen therapy was
reported in the women’s health initiative study, which
approached statistical significance, but combined oes-
trogen and progestogen therapy was associated with a
significantly increased annual risk of 8 per 10000 cases
after five years.7 12 22 WISDOM was unable to shed
light on the relation between progestogen and breast
cancer, although the data for all outcomes suggested
the greater safety of oestrogen only therapy, similar
to the results from the women’s health initiative trial.
Death—The apparent but non-significant increase in
mortality in users of combined therapy versus placebo
is not in keeping with a recent meta-analysis of all ran-
domised controlled trials of hormone replacement
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therapy (including the women’s health initiative),
which showed no increasedmortality overall and a sig-
nificantly reducedmortality in hormoneusers younger
than 60 years (odds ratio 0.67 (95% confidence interval
0.49 to 0.92)).23 The short follow-up time and small
number of deaths recorded in WISDOM do not
allow robust conclusions.
Limitations of study
The follow-up period in WISDOM was short because
of the early closure, and the power of the study was
greatly reduced by the curtailed recruitment, which
also led to relatively few women being in the younger
age groups. No conclusions can be drawn about the
outcomes in relation to these age groups.
Implications of results
InWISDOM only two hormone replacement therapy
regimens were studied, which contained conjugated
equine oestrogens and, when combined, medroxypro-
gesterone acetate. The medical profession and the
media must interpret and disseminate the results of
WISDOM with caution and responsibility. In 2002
unconsidered and sometimes exaggerated responses
to the first report from one arm of the women’s health
initiative study caused great alarm and distress to
women around the world, with many suddenly stop-
ping their hormone replacement therapywithoutmed-
ical consultation and in some cases with adverse
consequences.24 25
The results ofWISDOM, like those of thewomen’s
health initiative study, help test the hypothesis that
starting long term hormone replacement therapy in
elderly, often asymptomatic, women in their 60s
might reduce major morbidities, in particular cardio-
vascular disease.With the exception of fractures, this
does not seem likely. However, currently, such
women rarely start taking hormone replacement
therapy at these ages. Most women who start hor-
mone replacement therapy do so near the meno-
pause to reduce menopausal symptoms and
improve their quality of life. Clinical and animal stu-
dies suggest that the effect of oestrogen on the
cardiovascular system and possibly the brain may
be very different and probably beneficial when used
at or near the time of menopause.26-28 In particular, a
recent meta-analysis of 23 randomised controlled
trials of hormone replacement therapy showed that
it significantly reduced coronary heart disease in
women starting therapy younger than 60 years or
within 10 years of menopause.29 The early termina-
tion of WISDOM before large numbers of recently
menopausal women could be recruited, means that
the “critical window hypothesis” could not be exam-
ined to see if oestrogen has cardioprotective and neu-
roprotective effects.20 30 The risk:benefit equation for
a youngermenopausal womanmay be different from
that seen in the mainly older women in WISDOM
and the women’s health initiative study.
The publicity surrounding the first report from the
first arm of the women’s health initiative study put
great pressure on the funders of WISDOM to stop this
trial.15 31Details of themore favourable results from the
oestrogen only arm and the reanalyses of the women’s
health initiative study by age and years from meno-
pause, which suggested different results when hor-
mone replacement therapy is started in early
menopause, became available only several years after
the closure of WISDOM.32 A long term, randomised,
placebo controlled trial of hormone replacement ther-
apy from menopause is still needed but presents great
problems in terms of funding, compliance, and con-
tinuance, especially in symptomatic women.
Conclusions
The women’s health initiative study and WISDOM
have not answered the question about long term bene-
fits and risks of hormone replacement therapy in the
large majority of women who start therapy around
menopause for symptom control. However, they
have shown that there is no overall disease prevention
benefit, and somepotential risk, forwomenwith fewor
no oestrogen deficiency symptoms who start hormone
replacement therapy many years after menopause. If
there is amenopausal windowof therapeutic benefit its
upper limit has not been well defined and is likely to
vary with arterial health and associated risk factors
such as obesity and metabolic syndrome.33
Both the women’s health initiative study and WIS-
DOM were specifically looking for chronic disease
prevention in older postmenopausal women who did
not have disabling menopausal symptoms. An
increased quality of life associated with a reduction in
menopausal symptoms is the usual motivation for tak-
ing hormone replacement therapy. Quality of life data
from WISDOM will be published separately, and
these results should be considered alongside the main
morbidity and mortality outcome data described in
this paper. Those helping women make choices about
treatment should consider both the results and limita-
tions of the women’s health initiative study and WIS-
DOM, particularly those thatmay be influenced by the
timing of starting hormone replacement therapy.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Combined oestrogen and progestogen hormone replacement therapy initiated many years
after menopause in asymptomatic women reduces fracture risk but increases
thromboembolic, breast cancer, and possibly cerebrovascular risk
Oestrogen only hormone replacement therapy started near the menopausemay decrease the
risk of coronary heart disease, breast cancer, diabetes, and osteoporotic fractures
WHAT THIS STUDY ADDS
This study confirms an early increase in thromboembolic and cardiovascular risk in women
starting hormone replacement therapy at a mean of 63 years and 15 years after the
menopause
These uncommon serious events must be weighed against more common improvements in
quality of life
These results cannot be applied to symptomatic women starting hormone replacement
therapy near menopause, for whom cardiovascular benefits have recently been described
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